Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies.
Ian Flinn
Research Funding - Portola Pharmaceuticals
Manish R. Patel
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Anjali Pandey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Greg Coffey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Janet Leeds
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Stanley Hollenbach
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Sandra Russell
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Dale Baker
Employment or Leadership Position - Portola Pharmaceuticals
Consultant or Advisory Role - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Gallia G. Levy
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
John T Curnutte
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals